Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis has developed and validated novel production methods for the bacterial cancer vaccine currently in clinical trials. The original good manufacturing practice (GMP) batch of the Company’s Listeria-based immunotherapeutic which has been kept in a frozen state has been tested and found to be stable and to still meet release specifications approximately four years and nine months after manufacture.

“The ability to make a reproducible live Listeria vaccine with long-term storage stability is an essential part of the commercial development process,” commented Advaxis Chairman/CEO Thomas A. Moore. “As we continue to refine our FDA-approved production methods, further research may produce substantive improvements.”